Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingObservational

Characterization of T-cell Repertoire in Patients With AML Undergoing HSCT Through Next-Generation Sequencing of T Cell Receptor Alpha (TCRA) and T Cell Receptor Beta (TCRB) Genes

NCT ID: NCT03921047Sponsor: University of Southern CaliforniaLast updated: 2026-06-03

Summary

This research trial studies characterization of T-cell repertoire through next-generation sequencing in patients with acute myeloid leukemia undergoing stem cell transplant. Characterizing T-cell repertoire may help to understand if immune system plays a significant role in high risk patients with acute myeloid leukemia.

Detailed description

PRIMARY OBJECTIVES: I. Characterize the T cell receptor (TCR) repertoire in acute myeloid leukemia (AML) patients before and after receiving hematologic stem cell transplantation (HSCT). II. Identify molecular changes (germline variants and somatic mutations) that contribute to shaping the TCR repertoire. OUTLINE: Patents undergo collection of blood samples before, on day 100, and 1 year after HSCT. Donors undergo collection of blood at the time of HSCT for ribonucleic acid (RNA)-based next generation sequencing of TCRA and TCRB genes.

Arms & interventions

  • ProcedureBiospecimen Collection

    Undergo collection of blood samples

  • OtherLaboratory Biomarker Analysis

    Correlative studies

Outcome measures

Primary

  • Time to diagnosis of acute graft versus (vs.) host disease (aGVHD)

    Will be calculated as the time from stem cell infusion until the date of the diagnosis of aGVHD. If a patient dies prior to day 100 and does not have aGVHD, the patient will be censored at the time of death; all patients without aGVHD will be censored on day 100.

    Time frame: Up to 4 years

  • Time to diagnosis of relapse

    Will be calculated as the time from stem cell infusion until the date of the of the diagnosis of relapse Patients who die of treatment toxicity or other cause, prior to relapse, will be censored at the time of death; all patients will be censored at 365 days following transplant.

    Time frame: Up to 4 years

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * Diagnosis of AML scheduled to undergo HSCT at University of Southern California (USC) Exclusion Criteria: * Inability to provide consent because of severe mental disorders * Donor unwilling to provide consent

Study locations (1)

USC / Norris Comprehensive Cancer Center

Los Angeles, California, 90033

Recruiting
Houda Alachkar · Contact
Houda Alachkar · Principal Investigator
Characterization of T-cell Repertoire in Patients With Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant | Cancerify